Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

NCT07535242 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2026-04-17

No results posted yet for this study

Summary

This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.

Conditions

Sponsors & Collaborators

  • Ondokuz Mayıs University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-21
Primary Completion
2026-04-30
Completion
2026-05-05

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07535242 on ClinicalTrials.gov